Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

5.5%

11 terminated/withdrawn out of 199 trials

Success Rate

92.6%

+6.0% vs industry average

Late-Stage Pipeline

30%

59 trials in Phase 3/4

Results Transparency

38%

52 of 137 completed trials have results

Key Signals

19 recruiting52 with results10 terminated

Enrollment Performance

Analytics

Phase 1

72(39.6%)

Phase 3

56(30.8%)

Phase 2

51(28.0%)

Phase 4

3(1.6%)

182Total

Phase 1(72)

Phase 3(56)

Phase 2(51)

Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (199)

Showing 20 of 199 trials

NCT07104032Phase 3Recruiting

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Role: lead

NCT05079282Phase 1Active Not Recruiting

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Role: lead

NCT06547528Phase 1Active Not Recruiting

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Role: lead

NCT06803823Phase 2Recruiting

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

Role: lead

NCT07832747Phase 2Not Yet Recruiting

A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT

Role: lead

NCT07825402Phase 3Not Yet Recruiting

A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)

Role: lead

NCT07823790Phase 2Not Yet Recruiting

ONO-4915 in Patients With Primary Sjogren's Disease

Role: lead

NCT07818070Phase 3Not Yet Recruiting

A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma

Role: lead

NCT03661320Phase 3Completed

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Role: collaborator

NCT07749768Phase 1Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis

Role: lead

NCT07734116Phase 1Recruiting

A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

Role: lead

NCT07429266Phase 3Recruiting

INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

Role: lead

NCT03155061Phase 1Active Not Recruiting

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Role: lead

NCT06881836Phase 2Active Not Recruiting

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

Role: lead

NCT07787208Phase 1Recruiting

A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Role: lead

NCT03141177Phase 3Completed

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Role: collaborator

NCT04008030Phase 3Active Not Recruiting

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Role: collaborator

NCT06940791Phase 2Recruiting

Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)

Role: collaborator

NCT06816108Phase 1Active Not Recruiting

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Role: lead

NCT06622941Phase 2Recruiting

Study to ONO-4538 in Patients With Rhabdoid Tumor

Role: lead